Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for CHE and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for CHE and 80,000+ other tickers.
See exactly how CHE's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for CHE and 80,000+ other tickers.
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, doctors, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates through two segments: VITAS and Roto-Rooter segments. The company offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees. The company also provides direct medical services to patients, as well as…
Chemed (NYSE: CHE - Get Free Report) is expected to be releasing its Q3 2026 results after the market closes on Tuesday, October 27th. Analysts expect the company to announce earnings of $6.39 per share and revenue of $685.04 million for the quarter. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. Investors may visit
Chemed Corporation (NYSE: CHE - Get Free Report) has received an average rating of "Hold" from the seven research firms that are presently covering the firm, Marketbeat.com reports. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 1-year target price among
CINCINNATI, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will release financial results for the third quarter ended September 30, 2026, on Tuesday, October 27, 2026, following the close of trading on the New York Stock Exchange. Chemed will host a conference call and webcast at 10 a.m.
Chemed (NYSE: CHE - Get Free Report) and Mangoceuticals (NASDAQ: MGRX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations. Volatility and Risk Chemed has a beta of 0.51, suggesting